287 related articles for article (PubMed ID: 24749249)
1. [Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
Aĭsina RB; Mukhametova LI; Ostriakova EV; Seredavkina NV; Patrushev LI; Patrusheva NL; Reshetniak TM; Gulin DA; Gershkovich KB; Nasonov EL; Varfolomeev SD
Biomed Khim; 2014; 60(1):72-93. PubMed ID: 24749249
[TBL] [Abstract][Full Text] [Related]
2. [Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome].
Reshetniak TM; Ostriakova EV; Patrusheva NL; Patrushev LI; Aleksandrova EN; Seredavkina NV; Volkov AV; Nasonov EL
Ter Arkh; 2013; 85(1):76-84. PubMed ID: 23536951
[TBL] [Abstract][Full Text] [Related]
3. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome.
Tàssies D; Espinosa G; Muñoz-Rodríguez FJ; Freire C; Cervera R; Monteagudo J; Maragall S; Escolar G; Ingelmo M; Ordinas A; Font J; Reverter JC
Arthritis Rheum; 2000 Oct; 43(10):2349-58. PubMed ID: 11037896
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus].
Borisov EN; Krasnova TN; Samohodskaia LM; Ivanitskiĭ LV; Nikiforova NV; Mukhin NA
Ter Arkh; 2014; 86(6):57-62. PubMed ID: 25095657
[TBL] [Abstract][Full Text] [Related]
5. [PAL-1 5G/4G polymorphism in patients with systemic lupus erythematosus].
Savov A; Andonova S; Tanev D; Robeva R; Marincheva Ts; Tomova A; Kumanov P; Rashkov R; Kolarov Z
Akush Ginekol (Sofiia); 2014; 53(7):13-7. PubMed ID: 25675617
[TBL] [Abstract][Full Text] [Related]
6. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus.
Jiménez S; Tàssies D; Espinosa G; García-Criado A; Plaza J; Monteagudo J; Cervera R; Reverter JC
Ann Rheum Dis; 2008 Jun; 67(6):835-40. PubMed ID: 17728329
[TBL] [Abstract][Full Text] [Related]
7. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
Front Immunol; 2019; 10():885. PubMed ID: 31134052
[TBL] [Abstract][Full Text] [Related]
8. Genotype Ser413/Ser of PAI-2 polymorphism Ser413/Cys is associated with anti-phospholipid syndrome and systemic lupus erythematosus in a familial case: comparison with healthy controls.
Vázquez-Del Mercado M; García-Cobian TA; Muñoz Valle JF; Torres-Carrillo N; Martín-Márquez BT; Arana-Argaez VE; Best-Aguilera CR; Martínez-García EA; Petri MH; Núñez-Atahualpa L; Delgado-Rizo V
Scand J Rheumatol; 2007; 36(3):206-10. PubMed ID: 17657675
[TBL] [Abstract][Full Text] [Related]
9. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies.
Yasuda S; Tsutsumi A; Atsumi T; Bertolaccini ML; Ichikawa K; Khamashta MA; Hughes GR; Koike T
J Rheumatol; 2002 Jun; 29(6):1192-7. PubMed ID: 12064834
[TBL] [Abstract][Full Text] [Related]
10. [The levels of plasminogen and inhibitor of plasminogen activators of type 1 in antiphospholipid syndrome].
Ter Arkh; 2012; 84(5):50-7. PubMed ID: 22830213
[TBL] [Abstract][Full Text] [Related]
11. Endothelium-derived haemostatic factors and the antiphospholipid syndrome.
Mackworth-Young CG; Andreotti F; Harmer I; Loizou S; Pottinger BE; Pearson JD; Davies GJ; Maseri A; Walport MJ
Br J Rheumatol; 1995 Mar; 34(3):201-6. PubMed ID: 7728392
[TBL] [Abstract][Full Text] [Related]
12. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation.
Hisada R; Kato M; Sugawara E; Kanda M; Fujieda Y; Oku K; Bohgaki T; Amengual O; Horita T; Yasuda S; Atsumi T
J Thromb Haemost; 2019 Jul; 17(7):1134-1143. PubMed ID: 30864219
[TBL] [Abstract][Full Text] [Related]
13. Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients.
Bicakcigil M; Tasan D; Tasdelen N; Mutlu N; Yavuz S
Lupus; 2011 Oct; 20(10):1063-71. PubMed ID: 21719525
[TBL] [Abstract][Full Text] [Related]
14. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels.
de la Red G; Tàssies D; Espinosa G; Monteagudo J; Bové A; Plaza J; Cervera R; Reverter JC
Thromb Haemost; 2009 Feb; 101(2):312-6. PubMed ID: 19190815
[TBL] [Abstract][Full Text] [Related]
15. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
[TBL] [Abstract][Full Text] [Related]
16. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
17. The -675 4G/5G
Anaya-Macias BU; De la Cruz-Mosso U; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla G; González-López L; Gámez-Nava JI; Pérez-Guerrero EE; Barrientos-Avalos SL; Muñoz-Valle JF
Autoimmunity; 2020 Mar; 53(2):71-77. PubMed ID: 31829037
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case-control study.
Prabhudesai A; Shetty S; Ghosh K; Kulkarni B
Eur J Haematol; 2017 Sep; 99(3):249-254. PubMed ID: 28561456
[TBL] [Abstract][Full Text] [Related]
19. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome.
Forastiero R; Martinuzzo M; Adamczuk Y; Varela ML; Pombo G; Carreras LO
Haematologica; 2001 Jul; 86(7):735-41. PubMed ID: 11454529
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome.
Singh NK; Gupta A; Behera DR; Dash D
Rheumatol Int; 2013 Sep; 33(9):2331-6. PubMed ID: 23519427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
